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Abstract
Background: Recently released American College of Cardiology/American Heart Association (ACC/AHA) guideline
recommends the Pooled Cohort equations for evaluating atherosclerotic cardiovascular risk of individuals. The
impact of the clinical input variable uncertainties on the estimates of ten-year cardiovascular risk based on ACC/
AHA guidelines is not known.
Methods: Using a publicly available the National Health and Nutrition Examination Survey dataset (2005–2010),
we computed maximum and minimum ten-year cardiovascular risks by assuming clinically relevant variations/
uncertainties in input of age (0–1 year) and ±10 % variation in total-cholesterol, high density lipoprotein- cholesterol,
and systolic blood pressure and by assuming uniform distribution of the variance of each variable. We analyzed the
changes in risk category compared to the actual inputs at 5 % and 7.5 % risk limits as these limits define the thresholds
for consideration of drug therapy in the new guidelines. The new-pooled cohort equations for risk estimation were
implemented in a custom software package.
Results: Based on our input variances, changes in risk category were possible in up to 24 % of the population cohort
at both 5 % and 7.5 % risk boundary limits. This trend was consistently noted across all subgroups except in African
American males where most of the cohort had ≥7.5 % baseline risk regardless of the variation in the variables.
Conclusions: The uncertainties in the input variables can alter the risk categorization. The impact of these variances on
the ten-year risk needs to be incorporated into the patient/clinician discussion and clinical decision making.
Incorporating good clinical practices for the measurement of critical clinical variables and robust standardization of
laboratory parameters to more stringent reference standards is extremely important for successful implementation of the
new guidelines. Furthermore, ability to customize the risk calculator inputs to better represent unique clinical
circumstances specific to individual needs would be highly desirable in the future versions of the risk calculator.
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Background
The recent American College of Cardiology/American
Heart Association (ACC/AHA) guideline on the treat-
ment of blood cholesterol to reduce atherosclerotic car-
diovascular disease (ASCVD) risk in adults recommends
the use of the new pooled cohort equations to calculate
ten-year risk to help define the population cohorts that
are likely to benefit from either the initiation of statin
therapy in non-diabetics or define the intensity of statin
therapy in patients with diabetes for the primary preven-
tion of ASCVD [1, 2]. These equations were derived
from analyzing five major longitudinal studies that in-
clude the Framingham Heart Study (FHS and offspring
cohort) [3–5], the Coronary Artery Risk Development in
Young Adults (CARDIA) [6], the Cardiovascular Health
Study (CHS) [7], and the Atherosclerosis Risk in Commu-
nities Study (ARIC) [8]. The equations incorporate sex-
and race-specific proportional hazards models consisting
of covariates of objectively measured values of systolic
blood pressure (BP), total-cholesterol (c) and HDL-c with
other clinical and demographic features to calculate ten-
year risk of ASCVD. A risk calculator is available for
download [http://my.americanheart.org/cvriskcalculator].
The ten- year risk assessment has profound implica-
tions for clinical decision-making for an individual pa-
tient and for formulating health policies for primary
prevention [9, 10]. Application of the pooled cohort
equations to the National Health and Nutrition Examin-
ation Survey (NHANES) dataset from 2007 to 2010 re-
veals that approximately 20 % of the US population
(about 20 million people) have predicted ten- year risk
between 5 and 9.9 % and are therefore potential candi-
dates for statin therapy [11]. Despite multiple recent
analyses that suggest good calibration in general popula-
tion based cohorts [12–14], there is a considerable on-
going debate about the value of the new pooled cohort
equations as a tool to define thresholds for drug therapy
including the major impact of advanced age on calcu-
lated risk [15]. When the risk equations are applied to a
distinct population cohort different from original studied
cohorts, there has been conflicting data. Application of
these risk equations to the Reasons for Geographic and
Racial Differences in Stroke (REGARDS) cohort demon-
strated that observed and predicted CVD risks at 5 years
were similar suggesting that these equations are well cal-
ibrated with moderate to good discrimination [14]. In
contrast when the risk equations are applied to the
Multi-Ethnic Study of Atherosclerosis (MESA) cohort,
there appears to be an overestimation of risk and a lack
of superior calibration or discrimination compared with
the older risk scores [16]. We have recently published
in-depth analysis of the ten-year risk equations [17] and
also described a modified treatment approach based on
ten year risk assessment [18].
Because risk equations represent mathematical best fit
based on the results of prospective cohort studies, certain
inherent uncertainties (i.e., predictive intervals) always
exist when applying group equation to the individual. This
aspect has been highlighted in the ten-year risk guidelines
and discussed elsewhere [1, 2, 19]. Another important as-
pect of the new pooled cohort equations that has not been
well described is the influence of the uncertainties in clin-
ical input measurements of the discrete variables that are
needed for risk calculation on ten-year risk. Age in the
longitudinal studies is usually expressed in years corre-
sponding to the last birthday which would indicate that
there can be a variance of up to 1 year compared to actual
age (for example 60.75 years = 60 years, indicating differ-
ence of 0.75 years). BP measurement is prone to a number
of errors and uncertainties [15]. Furthermore, in CARDIA,
ARIC and CHS, a random zero sphygmomanometer was
used that produces readings 2–3 mmHg lower than man-
ual sphygmomanometer [20, 21]. In contrast, in FHS, BP
measurements were made with a mercury-column sphyg-
momanometer and the average of two physician-obtained
measures constituted the examination BP. This approach
is markedly different from routine clinical practice. Simi-
larly for total-c and HDL-c, the measurement results in
longitudinal studies were generally standardized to those
of a reference laboratory. The National Cholesterol
Education Program (NCEP) guidelines recommend total
analytical error in clinical models for the measurement of
total-c of ≤ 9.6 % and HDL-c of ≤ 13.3 % [22]. These oper-
ating characteristics may not hold true for many commer-
cial assays [23]. Moreover the clinical labs are certified to
Clinical Laboratory Improvement Amendment (CLIA)
standards where the acceptable total error for total-c is
±10 %, and for HDL-c is ±25 % [24].
Based on the hazard ratio of each variable to the ten-
year risk [1, 2], the variations/uncertainties in age, systolic
BP, HDL-c and total-c may have a significant influence on
the ten-year ASCVD risk. It is therefore conceivable that
due to the uncertainties in the input values of these
variables in routine clinical practice, there is variable
categorization of individuals into a high or low risk group-
ing, which in turn may cause erroneous management de-
cisions based on the guidelines. Therefore it is important
to define the effects of the input uncertainties to the risk
calculation. Here, we evaluate the influence of these un-




We used the publicly available NHANES dataset
(2005–2010). Participants with all the variable values
required for ten- year risk calculation between ages 40–75
years were included (n = 2355, Table 1 describes the
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baseline characteristics). Age was reported based on last
birthday (i.e., age in completed years) calculated by sub-
tracting the date of birth from the reference date, with the
reference date being the date of contact with an individual.
Gender and treatment for hypertension was self-reported.
Diabetes mellitus (DM) included self-reported physician
diagnosis or fasting plasma glucose of ≥126 mg/dL or a
hemoglobin A1c ≥ 6.5 %. Current smokers were persons
who smoked 100 cigarettes and who currently smoked
every day or some days. Race was self-reported based on
1997 Revisions to the Standards for the Classification of
Federal Data on Race and Ethnicity [25]. Total-c and
HDL-c measurements were using standard methods
as described [26]. Individuals with self-reported cor-
onary artery disease, heart attack (or myocardial infarc-
tion), angina and stroke were excluded.
Pooled cohort equations analysis
The new pooled cohort equations were implemented in
a custom software package (MATLAB, Natick, MA).
Our version of the risk calculator is available online [18].
Predicted ten-year risk for a given set of parameters for
the NHANES database (called ‘base calculated’ risk in
this paper) along with possible maximum and minimum
risks were computed by assuming a variation in age of
0–1 year, and a ± 10 % variation in total-c, HDL-c, and
systolic BP. The change in risk category at 5 % and/or
7.5 % risk boundary limits were analyzed. These bound-
ary limits were chosen as these define thresholds for dis-
cussion of drug therapies in the new guidelines. For the
patient cohort with base calculated risk < (less than) the
boundary limits, the percentage of the designated patient
cohort that had maximum possible risk ≥ (greater or
equal to) the boundary limits indicated the potentially
re-categorized population that may be eligible for more
intensive therapy but were deemed lower risk based on
base calculated measurement (Fig. 1). On the other
hand, for the patient cohort with base calculated




Ethnicity (N = 1805)
AA/White/Hispanic, % 29/48/23 38/62/0
Male/Female, % 45/55 46/54
Age, yrs 60 ± 10 60 ± 10
Total Cholesterol, mg/dl 200 ± 41 199 ± 41
HDL Cholesterol, mg/dl 53 ± 17 54 ± 17
Blood Pressure, mmHg 133 ± 20 133 ± 20
Diabetes, % 32 28
Smoker, % 16 17
Hypertension, % 89 90
Values are n, % or mean ± standard deviation
AA African-American
Fig. 1 Illustration of four classification scenarios according to boundary limit of 7.5 % due to the uncertainty of clinical measurements on
predicted ten-year atherosclerotic cardiovascular disease risk using the new pooled cohort equations. Scenario a, the base calculated ten-year risk is
well below the boundary limit, the variation in clinical measurements does not result in the change in risk category; For scenario b when the base
calculated ten-year risk is below or close to the boundary limit, and scenario c when the base calculated ten-year risk is equal to or slightly beyond the
boundary limit, the variation in clinical measurements may result in the change in risk category; Scenario d, the base calculated ten-year risk is well
beyond the boundary limit, the variation in clinical measurements does not result in the change in risk category
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risk ≥ the boundary limits, the percentage of the desig-
nated population that had minimum possible risk < the
boundary limits indicated the re-categorized population
that may be eligible for more conservative therapy but
were deemed higher risk based on baseline calculated
measurement (Fig. 1). For the primary analysis, we ana-
lyzed white and African American (AA) ethnicity (com-
bined whites and AA N= 1805) because the ACC/AHA
risk guidelines were primarily based on the white/AA
population. We also performed secondary analysis for all
participants that includes Hispanic ethnicity (n = 2355)
(Data Supplement).
Statistical analysis
The change in risk category at 5 % and/or 7.5 % risk
boundary limits were assessed by the Fisher’s exact test
(SAS 9.4). A P < 0.05 was considered statistically signifi-
cant. Total number of cohort with possible risk category
changes was defined as the total number of differences
in base calculated risk and maximum risk in the patient
cohort with base calculated ten-year risk < the boundary
limits (i.e., for 7.5 % boundary limit, N[Base Calculated Risk
<7.5%] –N[no change in risk categorization compared to base risk
<7.5%]) and differences in base calculated risk and mini-
mum risk in the patient cohort with baseline calculated
ten-year risk ≥ the boundary limits (i.e., for 7.5 % bound-
ary limit, N[Base Calculated Risk ≥7.5%] –N[no change in risk
categorization compared to base risk ≥7.5%]). Percentage of total
risk categorization changes was defined as the percent
total number of cohort with possible risk category
changes to the total patient cohort.
Results
In Figs. 2, 3 and 4, we provide the examples of applica-
tion of the modified calculator [18] with customizable
uncertainty limits for the realistic case scenarios. For
these case scenarios, the calculated maximum and mini-
mum risk based on the variations/ uncertainties of
rounding of age and measurements of total-c, HDL-c
and systolic BP reveals that the upper and lower bound-
ary limits of ten-year risk crosses the 5 % and 7.5 %
boundary limits (Figs. 2, 3 and 4). Thus, due to effect of
input variable uncertainties, base-calculated risk cat-
egory could be potentially increased from <5 % to ≥5 %
Fig. 2 Example illustrating the modified calculator with customizable uncertainty limits for a white female with baseline calculated ten-year risk of
3.5 %. The uncertainty in the measurement values of age, total-c, HDL-c and BP can be input using this customizable tool. The blue bar depicts
the calculated baseline ten-year risk, and the red bar represents the maximum and minimum risk. In the depicted example, maximum and minimum
risks were computed by assuming variations in input of age (0–1 year) and ± 10 % variation in total-cholesterol (c), HDL-c, and systolic blood pressure.
Boundary limits of 5 % and 7.5 % are marked by dashed and solid line, respectively. Our version of the risk calculator is available online [18]
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for patient in Fig. 2 or decreased from ≥7.5 % to <7.5 %
in patient in Fig. 4. For example depicted in Fig. 3 with
base-calculated risk of 5.8 %, risk category could poten-
tially range from low risk (<5 % boundary limit) to a
higher risk (≥7.5 % boundary limit).
Using modified calculator [18], we determined the
base and the upper and lower boundary limits of ten-
year risk for our study cohort. Baseline characteristics of
the participant cohort are described in Table 1. Our
detailed analysis dataset of NHANES data is attached
as Additional file 1.
For the primary analysis, we analyzed white and AA
ethnicity (combined N= 1805). We find that around
33 % of the total cohort had base calculated risk of <
7.5 % while the other 67 % had base calculated risk
≥7.5 %. On evaluating the possible risk category changes,
up to 38 % of the cohort with base calculated risk
<7.5 % (12.57 % of total cohort) may have ≥7.5 % risk
based on possible risk. These may therefore need to be
treated more aggressively. Furthermore, up to 17 % of
the cohort with base calculated risk ≥7.5 % (12.36 % of
total cohort) may be re-categorized based on their
possible minimum risk, indicating that these individ-
uals may not be treated appropriately. This trend was
consistently noted across all subgroups except for
African American males where most of the cohort
had ≥ 7.5 % baseline risk regardless of the variation in
the variables (Table 2).
We also calculated possible changes in risk category
based on the variation described at 5 % boundary limit
for non-diabetics (Table 3).
We find similar trends and results for possible risk re-
categorization as for 7.5 % boundary limit for the total
cohort and the subgroups except for African American
males for <5 % risk where the number of possible
change in risk category did not reach statistical signifi-
cance as most of the cohort had ≥ 5 % baseline risk re-
gardless of the variation in the variables. When we
incorporated Hispanics and calculated the risk based on
white cohort (as per the guideline recommendations),
we find that the results remained consistent (Additional
file 2: Table S1 and Additional file 3: Table S2).
Discussion
Our analysis of the new-pooled cohort equations for
ten-year ASCVD risk quantification provides important
caveats that need to be considered: a) The variations/
uncertainties in the input values of continuous variables
Fig. 3 Example illustrating the modified calculator with customizable uncertainty limits for a white male with baseline calculated ten-year risk of
5.8 %. Explanations and abbreviations as in Fig. 2
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(age, systolic BP, total-c and HDL-c) used for ten-year
risk calculation have an important effect on the calcu-
lated ten-year risk; b) At the proposed important deci-
sion nodes of 5 % and 7.5 % ten-year risk, we find that
these variations/ uncertainties in the input values can in-
fluence the categorization into a high or low risk group-
ing in a substantial number of people. This therefore
may have important effects on treatment planning and
preventive policies. Uncertainty is a quantification of the
doubt about the measurement results [27]. Any param-
eter which influences the risk calculation, and whose
value we do not know precisely, is a source of uncer-
tainty [1]. We report our results based on 0–1 year un-
certainty, assuming that the age of individual is typically
rounded or truncated based on how his date of birth
compared to the date of encounter. The ACC/AHA risk
calculator allows for inputting precise age in years (using
decimal numbers) which is likely to reduce the uncer-
tainty in the absolute calculated risk and should there-
fore be taken into account when calculating ten-year
risk. Defining uncertainties in routine clinical practice of
systolic BP, total-c and HDL-c for calculating 10-year
risk is more challenging. The measurements uncertainty
(coefficient of variance) of a particular assay is generally
reported by the manufactures and similar test character-
istics should therefore be replicated wherever the test is
performed in a clinical setting. In clinical reports these
known uncertainty/variability due to known test charac-
teristics are not generally reported. There are additional
parameters that can affect the certainty of the measure-
ments, which may be due to biological factors and/envir-
onmental factors or other undefined reasons, and are
therefore difficult to quantify. This latter aspect is likely
more important for BP measurements. Guidelines have
been proposed regarding optimal techniques for BP
measurement including instrumentation [15]. Adhering
to these guidelines may reduce some of the well described
uncertainties in the clinical BP measurements [15, 28]. Al-
though CLIA standards are frequently used for clinical
labs, NCEP standards for total and HDL-c are more strin-
gent. The use of repeated measures has been previously
shown to improve risk prediction by reducing regression
dilution bias and providing more stable risk factor values
[29]. Therefore, in patients with borderline risk (e.g. be-
tween 5-7.5 %), it may be prudent to perform repeat mea-
surements (at a certain time apart, preferably triplicate
Fig. 4 Example illustrating the modified calculator with customizable uncertainty limits for African American male with baseline calculated ten-
year risk of 7.9 %. Explanations and abbreviations as in Fig. 2
Gupta et al. BMC Cardiovascular Disorders  (2016) 16:165 Page 6 of 10
Table 2 Analysis of the impact of input variable variations in categorizing subjects based on ten-year risk threshold of 7.5 %





No change of risk
categorization (Maximal
calculated risk <7.5 %)
Change of risk
categorization (Maximal
calculated risk ≥7.5 %)
Base Calculated
Risk ≥7.5 %
No change of risk
categorization (Minimal
calculated risk ≥7.5 %)
Change of risk
categorization (Minimal
calculated Risk <7.5 %
All (n = 1805) 32.96 20.39*** 12.57 67.04 55.68*** 11.36 23.93
Non-DM (n = 1292) 41.80 26.55*** 15.25 58.20 46.90*** 11.3 26.55
AA (n = 426) 36.15 20.42*** 15.73 63.85 52.11*** 11.74 27.46
AA Male (n = 196) 14.29 6.63* 7.66 85.71 78.57 7.14 14.80
AA Female (n = 230) 54.78 32.17*** 22.61 45.22 29.57*** 15.65 38.26
White (n = 866) 44.57 29.56*** 15.01 55.43 44.34*** 11.09 26.10
White Male (n = 404) 34.90 19.31*** 15.59 65.10 52.72*** 12.38 27.97
White Female (n = 462) 53.03 38.53*** 14.5 46.97 37.01*** 9.96 24.46
DM (n = 513) 10.72 4.87*** 5.85 89.28 77.78*** 11.5 17.35
AA (n = 255) 5.88 2.35 3.53 94.12 84.71*** 9.41 12.94
AA Male (n = 107) 0.00 0.00 0 100.00 98.13 1.87 1.87
AA Female (n = 148) 10.14 4.05 6.09 89.86 75.00** 14.86 20.95
White (n = 258) 15.50 7.36*** 8.14 84.50 70.93*** 13.57 21.71
White Male (n = 130) 10.77 3.85 6.92 89.23 81.54 7.69 14.62
White Female (n = 128) 20.31 10.94 9.37 79.69 60.16** 19.53 28.91
Values are % or n. Base calculated: predicted ten-year risk using the raw NHANES data; Minimal Risk: minimum predicted ten-year risk computed by the calculator assuming a variation in age of 0–1 year, and ± 10 %
variation in total-cholesterol (c), HDL-c, and systolic blood pressure (BP); Maximal Risk: maximum predicted ten-year risk computed by the calculator assuming a variation in age of 0–1 year, and ± 10 % variation in
total-cholesterol (c), HDL-c, and systolic blood pressure (BP); DM: Diabetes mellitus; AA: African-American; Comparisons between Base versus Max/Min Risk were performed using Fisher’s Exact Test; * for P < 0.05, ** for














measurements). A similar approach has been previously
proposed in NCEP Adult Treatment Panel III guidelines
and in a US Preventive Services Taskforce statement that
recommends repeating the lipid profile to confirm ab-
normal values [http://www.uspreventiveservicestaskfor-
ce.org/uspstf08/lipid/lipidrs.htm [30],]. In addition, use
of NCEP network laboratories may be prudent in cer-
tain situation such as of wide variability in the meas-
urement values.
It should be emphasized that clinical judgement and
discussion with the individual patient is important
when deciding for optimal treatment approach based
on calculated ten-year risk. This aspect has also been
highlighted in the ten-year risk guidelines. Risk equa-
tions provide important guidance to the clinicians and
the patients for such discussion. However since these
equations represent mathematical functions/ best fit
based on the results of prospective cohort studies, they
do have inherent uncertainties and hence cannot super-
sede the judgement of a clinician. Our analysis does
have important limitations. The distribution function of
the variance of the continuous variables in actual clin-
ical situations is not well described. We calculated the
outermost boundaries of ten-year risk and the net un-
certainty assuming uniform distribution and predictable
direction in the variance of each variable. This therefore
would result in greater net risk re-categorization than
in clinical situations. However, we have provided a
practical framework for estimating the impact of uncer-
tainties in important clinical variables. Assessment of
the whole spectra of intermediate effects due to bidirec-
tional uncertainties in clinical variable measurements
as well as the assessment of relative role of specific in-
put variables on the risk re-categorization was not
considered in the present study. The relative interaction
of clinical input variable uncertainties and model inher-
ent uncertainties (i.e., group risk prediction intervals)
in individual risk predictions [19], was also beyond the
scope of the present study. Such analysis would require
much more sophisticated simulation and incorporating
data from large clinical datasets.
Based on our previous publications [17, 18] and present
work, we would suggest two additional features for the fu-
ture iterations of the risk calculator. Firstly, it should allow
the customizable input of uncertainty limits for relevant
variables based on the local or reference laboratory stan-
dards. Further, it should estimate the upper and lower
boundaries for ten-year ASCVD risk taking into account
various uncertainties including that for individual datasets
and model fits.
Conclusions
Our intent in writing this manuscript is to raise awareness
about certain aspects of the new pooled cohort equations
for ten-year risk calculation that are not immediately ap-
parent. We describe effects of the uncertainty in measure-
ments of important variables for calculating ten-year risk
that may have a significant impact in preventive ap-
proaches to ASCVD. Incorporating good clinical practices
for the measurement of critical clinical variables and ro-
bust standardization of laboratory parameters to more
stringent reference standards is extremely important for
successful implementation of the new guidelines. Further-
more, ability to customize the risk calculator inputs to bet-
ter represent unique clinical circumstances specific to
individual needs would be highly desirable in the future
versions of the risk calculator.
Table 3 Analysis of the impact of input variable variations in categorizing subjects based on ten-year risk threshold of 5 %


























Non-DM (n = 1292) 28.79 16.02*** 12.77 71.21 59.83*** 11.38 24.15
AA (n = 426) 23.47 10.80*** 12.67 76.53 65.49*** 11.04 23.71
AA Male (n = 196) 4.08 1.53 2.55 95.92 90.82 5.1 7.65
AA Female (n = 230) 40.00 18.70*** 21.3 60.00 43.91*** 16.09 37.39
White (n = 866) 31.41 18.59*** 12.82 68.59 57.04*** 11.55 24.36
White Male (n = 404) 22.77 10.89*** 11.88 77.23 66.34*** 10.89 22.77
White Female (n = 462) 38.96 25.32*** 13.64 61.04 48.92*** 12.12 25.76
Values are % or n. Base calculated: predicted ten-year risk using the raw NHANES data; Minimal Risk: minimum predicted ten-year risk computed by the calculator
assuming a variation in age of 0–1 year, and ± 10 % variation in total-cholesterol (c), HDL-c, and systolic blood pressure (BP); Maximal Risk: maximum predicted
ten-year risk computed by the calculator assuming a variation in age of 0–1 year, and ± 10 % variation in total-cholesterol (c), HDL-c, and systolic blood pressure
(BP); DM: Diabetes mellitus; AA: African-American; Comparisons between Base versus Max/Min Risk were performed using Fisher’s Exact Test; * for P < 0.05, ** for
P < 0.01, and *** for P < 0.001
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